Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Donald P. Quick

Hematology Oncology | Oncology
4101 22nd Place, 
Lubbock, TX 
Accepting New Patients
43 Years of Experience
Experienced in WT1-Related Wilms Tumor Syndromes
4101 22nd Place, 
Lubbock, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Donald Quick is a Hematologist Oncology specialist and an Oncologist in Lubbock, Texas. Dr. Quick has been practicing medicine for over 43 years and is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Non-Hodgkin Lymphoma, Hemangioma Thrombocytopenia Syndrome, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, and Bone Marrow Aspiration. Dr. Quick is currently accepting new patients.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1982
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in NM
Hospital Affiliations
Covenant Hospital Plainview
Nor-Lea Hospital District
University Medical Center
Covenant Medical Center
Covenant Childrens Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Scott and White Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Sky Community Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER COMMERCIAL
View 13 Less Insurance Carriers -

Locations

4101 22nd Place, Lubbock, TX 79410

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
Phase 1 Trial of Dose Escalated BGB324 in Combination With Docetaxel for Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 1 Trial of Dose Escalated BGB324 in Combination With Docetaxel for Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: February 21, 2024
Intervention Type: Drug
Study Drugs: BGB324, Docetaxel
Study Phase: Phase 1
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1 Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Durvalumab in Patients With Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
A Phase 1 Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Durvalumab in Patients With Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: October 26, 2021
Intervention Type: Drug
Study Phase: Phase 1
Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma
Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma
Enrollment Status: Terminated
Publish Date: August 27, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
Enrollment Status: Terminated
Publish Date: March 11, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

16 Total Publications

Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy.
Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy.
Journal: Reports (MDPI)
Published: May 23, 2024
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Thomas E. Hutson
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Thomas E. Hutson
Oncology | Hematology

Texas Tech University Health Sciences Center Lubbock

602 Indiana Ave, 
Lubbock, TX 
 (1.3 miles away)
806-743-1842
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Hutson is an Oncologist and a Hematologist in Lubbock, Texas. Dr. Hutson is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Adult Soft Tissue Sarcoma, and Renal Cell Carcinoma (RCC). Dr. Hutson is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David R. Close
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David R. Close
Oncology
4101 22nd Place, 
Lubbock, TX 
 (0.1 miles away)
806-725-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Close is an Oncologist in Lubbock, Texas. Dr. Close is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Paget Disease of the Breast, Inflammatory Breast Cancer, Breast Cancer, and Familial Colorectal Cancer. Dr. Close is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Lukman A. Tijani
Hematology Oncology | Oncology | Hematology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Lukman A. Tijani
Hematology Oncology | Oncology | Hematology

Texas Tech University Health Sciences Center Lubbock

602 Indiana Ave, 
Lubbock, TX 
 (1.3 miles away)
806-743-3150
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lukman Tijani is a Hematologist Oncology specialist and an Oncologist in Lubbock, Texas. Dr. Tijani is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Neuroendocrine Tumor, Bone Marrow Aspiration, and Endoscopy. Dr. Tijani is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Quick's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 51 Advanced Conditions
    View All 119 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile